Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease
Gastroenterology Research · 2026-06 · 19 (3) · 147-154
DOI: 10.14740/gr2136 ↗At a glance
Journal article in Gastroenterology Research, 2026-06. Written by Jonathan Weng and 5 co-authors. Institution: Department of Medicine, Tufts Medical Center, Boston, MA, USA. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Няма налично резюме.
Subjects
Author keywords
Authors and institutions
- Department of Medicine, Tufts Medical Center, Boston, MA, USA.
- These authors contributed equally to the manuscript.
- Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA, USA.
Cite
APA
Weng, J., Huang, A., Berake, T. B., Chen, S. L., Yan, B. M., & Karagozian, R. (2026). Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterology Research, 19(3), 147-154. https://doi.org/10.14740/gr2136
Vancouver
Weng J, Huang A, Berake TB, Chen SL, Yan BM, Karagozian R. Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterology Research. 2026;19(3):147-154. doi:10.14740/gr2136
BibTeX
@article{Weng2026,
author = {Weng, Jonathan and Huang, Anderson and Berake, Tamiru B and Chen, Sarah L and Yan, Brian M and Karagozian, Raffi},
title = {Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Gastroenterology Research},
year = {2026},
volume = {19},
number = {3},
pages = {147--154},
doi = {10.14740/gr2136}
}
EUVIMED